pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Awiqli FlexTouch
drug
save

insulin icodec

Marketedupdated 3mo ago
by Novo Nordisk Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 4
  • drugAWIQLI FLEXTOUCH4 co-mentions · 1 sources
  • tagApproval4 co-mentions · 1 sources
  • druginsulin2 co-mentions · 1 sources
  • companyNovo Nordisk Inc2 co-mentions · 1 sources

Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for diabetes mellitus and type 2 diabetes mellitus and 1 investigational indication.

indications

investigational
Type 2 Diabetes

all catalysts(1)

approval · 1
Mar 26, 2026
approval
$NVO44.88-0.95%
5mo ago
AWIQLI FLEXTOUCH (INSULIN ICODEC) — FDA approval
insulin icodec
→

Trials studying insulin icodec

  • phase1Clinical Trials of IBI3035 in Healthy Subjectsrecruitingn=144
  • phase3A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Beforecompletedn=1,085
  • —A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugaractive not recruitingn=245
  • phase3A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetesrecruitingn=877
  • phase3A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetescompletedn=148
  • phase3A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)completedn=51
  • phase1A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagerscompletedn=18
  • phase3A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetescompletedn=429
more trials →

News(0)

no news has mentioned this drug yet

brand
Awiqli FlexTouch
generic
insulin icodec-abae
MOA
Insulin receptor agonist
indication
Type 2 Diabetes
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 6m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?